Theodore R. Schroeder - 06 Jun 2022 Form 4 Insider Report for Nabriva Therapeutics plc

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
N/A
Transactions as of
06 Jun 2022
Net transactions value
-$45
Form type
4
Filing time
07 Jun 2022, 16:47:48 UTC
Previous filing
02 Jun 2022
Next filing
23 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRV Ordinary Shares Tax liability $45 -225 -0.07% $0.2000* 312,973 06 Jun 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.